Second, the KRAS mutation profiles in CRC cell lines and PDX tumors in our studies did not include the KRAS G12C mutation, which was targeted by KRAS G12C inhibitors (AMG510 and MRTX849); therefore, we could not compare the curable effect of RGS and these 2 promising compounds. This evidence concerns the gene KRAS and colorectal carcinoma.